Breaking News
Get 40% Off 0
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks. Unlock full list
Close

Gilead Sciences Inc (GILD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
66.620 0.000    0.00%
07/03 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 66.000 / 67.300
  • Day's Range: 66.620 - 66.660
Type:  Equity
Market:  Austria
ISIN:  US3755581036 
Gilead 66.620 0.000 0.00%

Gilead Company Profile

 
Read the Gilead company profile to learn more about the business and the management team. View Gilead Sciences Inc facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

18000

Equity Type

ORD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Contact Information

Address 333 Lakeside Drive
Foster City, 94404
United States
Phone 650 574 3000
Fax 650 578 9264

Top Executives

Name Age Since Title
Daniel P. O'Day 57 2019 Chairman & CEO
Paul Berg 97 1998 Member of Scientific Advisory Board
Grace E. Colon 56 2023 Chairman of the Board
Joel R. Huff - - Chairperson of Scientific Advisory Board
Kelly A. Kramer 56 2016 Independent Director
Javier J. Rodriguez 53 2020 Independent Director
Sandra J. Horning 75 2020 Independent Director
Jeffrey A. Bluestone 71 2020 Independent Director
Ted W. Love 65 2024 Independent Director
Jacqueline K. Barton 71 1989 Independent Director
Eugene R. Schiff - - Member of the Scientific Advisory Board
John W. Mellors 86 - Member of the Scientific Advisory Board
Harish M. Manwani 71 2018 Independent Director
Eric J. Topol 70 - Member of Scientific Advisory Board
Robert A. Harrington 63 - Member of the Scientific Advisory Board
Paul E. Klotman - - Member of the Scientific Advisory Board
Francis V. Chisari - - Member of the Scientific Advisory Board
Robert T. Schooley - - Member of the Scientific Advisory Board
Nezam H. Afdhal 67 - Member of Scientific Advisory Board
Mark C. Genovese - - Member of Scientific Advisory Board
Malcolm MacCoss 76 - Member of Scientific Advisory Board
Anthony Welters 69 2020 Lead Independent Director
Kenneth C. Anderson 73 - Member of the Scientific Advisory Board
Brian J. Druker 68 - Member of the Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GILD Price Commentary

Write your thoughts about Gilead Sciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Oc Masai
Oc Masai Apr 27, 2021 7:54
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good job GILD. bullish move forward
Ashraf Elgendy
Ashraf Elgendy Mar 07, 2021 13:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
RM RM
RM RM Mar 01, 2021 21:53
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Up Again
Ken Laing
Ken Laing Oct 23, 2020 18:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time to load up before the big rise coming next week
Iggy Maldon
Iggy Maldon Jul 30, 2020 20:22
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Classic pump n’ dump. What a shambles
RM RM
RM RM May 28, 2020 22:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will reach above 95
Chili Daug
Chili Daug May 28, 2020 22:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
when? hahah
SAGAR AGARWAL
SAGAR AGARWAL May 15, 2020 14:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good time to accumulate.
Khizer Malik
Khizer Malik May 14, 2020 11:04
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
Willy Chin
Willy Chin Apr 23, 2020 18:14
Saved. See Saved Items.
This comment has already been saved in your Saved Items
High chance to be trading above 90, good long stock
Viktor Veselý
Viktor Veselý Apr 12, 2020 7:48
Saved. See Saved Items.
This comment has already been saved in your Saved Items
By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email